Day: February 24, 2026

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults TARRYTOWN, N.Y. and PARIS, Feb. 24, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adultsParis and Tarrytown, NY, February 24, 2026. The US Food and Drug Administration (FDA)...

U.S. spot ETF expands regulated access to the Sui ecosystem as institutional momentum accelerates NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) — 21shares, one of the world’s leading issuers of crypto exchange-traded funds (ETFs), today announced the launch of the 21shares Spot SUI ETF (TSUI), which has officially started trading on Nasdaq. TSUI allows U.S. investors to integrate SUI into their portfolios via traditional brokerage accounts, without the need to directly hold or manage digital wallets. TSUI is not registered under the Investment Company Act of 1940, as amended (” ’40 Act”), and is not subject to the same regulations and protections as ’40 Act registered ETFs and mutual funds. TSUI is subject to significant risk and heightened volatility. SUI assets are not suitable for an investor who cannot afford...

Accelerates time to book; more than doubles internal productivity; advances Fleet Rocket sales HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a technology-centric logistics company offering a diversified portfolio of AI software solutions designed to address key inefficiencies in the supply chain, today announced strong productivity gains across key operating metrics for customers and its internal operations. The Company’s intelligence-led and automation-driven solutions are improving the pace, accuracy, and scale of customers’ freight management, while providing revenue synergies and margin improvements for Fr8Tech. Over the past year, Freight Technologies has deployed proprietary, agentic AI systems across its existing offerings, including Fr8App for over-the-road,...

Keith HopkinsVP, Content Distribution & Marketing for TV One NetworksSILVER SPRING, MD., Feb. 24, 2026 (GLOBE NEWSWIRE) — TV One Networks today announced the appointment of Keith Hopkins as the new Vice President of Content Distribution & Marketing. Hopkins brings two decades of experience spanning content distribution, sports partnerships, and streaming strategy, having held senior leadership roles at Roku, Nexstar Media Group, Pac-12 Conference and NBCUniversal/Comcast. In his new role, Hopkins will lead the company’s distribution and partnership marketing strategy across all linear and digital platforms, domestically and internationally, maximizing reach and revenue opportunities for TV One and CLEO TV.  Most recently at Roku, Hopkins helped lead sports and news distribution strategy, securing major licensing...

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas 10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalpWESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that six-time PGA Tour winner Max Homa has joined the company’s Free to Be Me awareness campaign...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live audio of the webcast will be available on the Events page of the Investors section of the Company’s website (sentibio.com). Interested parties may...

Pilot program to bring one of the world’s most iconic FMCG brands onto SemiCab’s collaborative AI platform; aims to cut transportation costs and reduce empty miles for iconic beverage brand Fort Lauderdale, FL, Feb. 24, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – a leading AI technology company, today announced that SemiCab has been awarded a pilot program with Hindustan Coca-Cola Beverages Private Limited (“Coca-Cola India”), a subsidiary of The Coca-Cola Company and its largest bottling partner in India, to launch a pilot transportation program on SemiCab’s collaborative freight platform. SemiCab will onboard Coca-Cola India onto SemiCab’s Collaborative Transportation Platform, marking a major milestone in SemiCab’s expansion within India’s fast-moving consumer goods (FMCG) sector. The deal...